KLRK1 and B-cell chronic lymphocytic leukemia: Treatment of PBMCs obtained from CLL patients with IL-2 and IL-15 for 48 hours significantly up-regulated the expression of NKG2D on NK cells and CD8 T cells (Fig. 6A).